Yes, Medi-Cal does cover hormone replacement therapy for menopause. A broad range of FDA-approved estrogen and progestogen products appear on the Medi-Cal Rx Contract Drugs List, which is the statewide formulary for outpatient prescriptions, and beneficiaries can get them filled with a prescription from any provider who accepts Medi-Cal.1Medi-Cal Rx (DHCS). Drug Use Review: Menopausal Hormone Therapy for Bothersome Vasomotor Symptoms Several non-hormonal medications for menopausal symptoms are covered too.
Which Hormone Therapies Are Covered
The Contract Drugs List includes estradiol in tablets, transdermal patches, and vaginal cream or ring; conjugated estrogens in tablets, capsules, and vaginal cream; and esterified estrogens in tablets and capsules. On the progestogen side, the list covers micronized progesterone capsules and norethindrone acetate with ethinyl estradiol tablets. As of February 2026, additional strengths of conjugated estrogens (0.45 mg) and a conjugated estrogen–medroxyprogesterone acetate combination (0.3 mg–1.5 mg and 0.45 mg–1.5 mg) were added.2Medi-Cal Rx (DHCS). Medi-Cal Rx Contract Drugs List
According to a California Health Benefits Review Program analysis, every Medi-Cal enrollee has baseline coverage for most oral, topical systemic, and transdermal hormone therapies with no utilization management requirements. Laboratory tests used to evaluate menopausal symptoms are fully covered on the same terms.3California Health Benefits Review Program. Analysis of Assembly Bill 432: Menopause
Treatment is approved for the common reasons people seek it: vasomotor symptoms like hot flashes and night sweats, genitourinary syndrome of menopause, and primary ovarian insufficiency.
Non-Hormonal Options
If you can’t take hormones or don’t want to, Medi-Cal also covers several non-hormonal prescription medications used for menopausal symptoms:
- SNRIs: venlafaxine and desvenlafaxine
- SSRIs: citalopram, paroxetine, and escitalopram
- Fezolinetant, an NK3 receptor antagonist approved specifically for hot flashes
- Gabapentin in tablets, capsules, and oral solution
- Oxybutynin in patches, tablets, and syrup, which can also help with hot flashes
The Medi-Cal Drug Use Review program also recognizes non-drug approaches such as cognitive behavioral therapy, clinical hypnosis, weight loss, and stellate ganglion blockade as options for managing vasomotor symptoms.1Medi-Cal Rx (DHCS). Drug Use Review: Menopausal Hormone Therapy for Bothersome Vasomotor Symptoms
How To Get HRT Through Medi-Cal
Start with a visit to a healthcare provider. Any prescriber can write the prescription: primary care physicians, OB/GYNs, endocrinologists, nurse practitioners, and physician assistants are all qualified. The provider will go through your medical history, confirm you have bothersome menopausal symptoms, screen for anything that would rule out hormone therapy, and talk through the options with you.1Medi-Cal Rx (DHCS). Drug Use Review: Menopausal Hormone Therapy for Bothersome Vasomotor Symptoms
Since January 2022, all outpatient prescription drugs for Medi-Cal beneficiaries have been handled through the Medi-Cal Rx program on a fee-for-service basis. That applies whether or not you’re in a managed care plan.4California Health Benefits Review Program. Analysis of SB 418: Prescription Hormone Therapy and Nondiscrimination Once your provider writes a prescription for a drug on the Contract Drugs List, you fill it at a pharmacy that accepts Medi-Cal. The state keeps the current formulary on the Medi-Cal Rx web portal.
Clinical Limits on Who Can Be Prescribed HRT
Medi-Cal follows standard clinical guidelines. Providers are expected to prescribe the lowest effective dose, and non-oral routes like patches and vaginal preparations may be preferred for some patients because of their risk profile.
One rule matters for most people considering systemic estrogen: if you have an intact uterus, you also need a progestogen to protect against endometrial cancer. If you’ve had a hysterectomy, estrogen alone is appropriate.1Medi-Cal Rx (DHCS). Drug Use Review: Menopausal Hormone Therapy for Bothersome Vasomotor Symptoms
Hormone therapy is considered most beneficial when started before age 60 or within 10 years of menopause onset. Starting it later, in someone older than 60, or continuing it past age 65 triggers a formal shared decision-making process that weighs risks and benefits more carefully.
Conditions that generally rule out hormone therapy include unexplained vaginal bleeding, liver disease, a history of estrogen-sensitive cancer such as breast cancer, coronary heart disease, prior stroke or heart attack, venous thromboembolism, and severely uncontrolled blood pressure above 180/110.1Medi-Cal Rx (DHCS). Drug Use Review: Menopausal Hormone Therapy for Bothersome Vasomotor Symptoms
Compounded Bioidentical Hormones
Compounded bioidentical hormone therapies are generally not recommended under Medi-Cal. Program guidance cites inconsistent dosing from manufacturing variability, potential impurities, sterility issues, limited scientific data, and minimal government oversight. They’re considered appropriate only in narrow cases: when a patient has a documented allergy to an ingredient in an FDA-approved product, or when a needed dose simply isn’t available in any approved formulation.1Medi-Cal Rx (DHCS). Drug Use Review: Menopausal Hormone Therapy for Bothersome Vasomotor Symptoms
Drugs That Face Extra Hurdles
Common oral and transdermal hormone therapies move through without utilization management, but some treatments carry restrictions. The CHBRP analysis identified topical testosterone, high-dose vaginal estrogen, fezolinetant, ospemifene, and prasterone as having utilization management at baseline across California health plans, including Medi-Cal managed care. Osteoporosis medications also carry utilization management across the board.5California Health Benefits Review Program. Key Findings: Analysis of Assembly Bill 432 Drugs not on the Contract Drugs List may still be covered, but they require authorization from a Medi-Cal consultant.
Pending Changes That Could Expand Coverage
Two proposals could reshape menopause coverage under Medi-Cal, and both were still pending in mid-2026.
A February 2026 budget trailer bill proposed by Governor Newsom would add Section 14132.14 to the Welfare and Institutions Code, making FDA-approved menopause treatments a covered Medi-Cal benefit subject to medical necessity, and would direct the Department of Health Care Services to set reimbursement policies and consider Menopause Society clinical guidelines.6California Department of Finance. Trailer Bill 1385: Menopause Health Care Coverage The same bill text exempts Medi-Cal managed care plans from several provisions that would apply to commercial insurers, including menopause screening requirements and utilization review reforms. Assemblymember Rebecca Bauer-Kahan called the exclusion a “gaping hole” and a “significant equity issue,” noting that the program serves 7.6 million women and girls who are disproportionately Black and Latina.7Capital and Main. From Invisibility to Inclusion: A Generational Shift on Menopause Care
SB 418, which does apply to Medi-Cal, would require coverage of up to a 12-month supply of FDA-approved prescription hormone therapy and would prohibit utilization controls that limit the supply to less than 12 months.4California Health Benefits Review Program. Analysis of SB 418: Prescription Hormone Therapy and Nondiscrimination If passed, it would make it easier to pick up a full year of HRT in one go instead of refilling in smaller increments.